|
Originally published In Press as doi:10.1074/jbc.M107054200 on September 19, 2001
J. Biol. Chem., Vol. 276, Issue 48, 45015-45023, November 30, 2001
Thiomandelic Acid, a Broad Spectrum Inhibitor
of Zinc -Lactamases
KINETIC AND SPECTROSCOPIC STUDIES*,
Claire
Mollard §,
Catherine
Moali§¶,
Cyril
Papamicael§ ,
Christian
Damblon ,
Sandrine
Vessilier**,
Gianfranco
Amicosante**,
Christopher J.
Schofield ,
Moreno
Galleni¶,
Jean-Marie
Frère¶, and
Gordon C. K.
Roberts 
From the Biological NMR Centre, Department of
Biochemistry, University of Leicester, P.O. Box 138, University Rd.,
Leicester LE1 9HN, United Kingdom, ¶ Centre d'Ingénierie
des Protéines, Institut de Chimie B6, Université de
Liège, Sart-Tilman, B-4000 Liège, Belgium, The
Oxford Centre for Molecular Sciences and The Dyson Perrins Laboratory,
South Parks Rd., Oxford OX1 3QY, United Kingdom, and
** Dipartimento di Scienze e Tecnologie Biomediche,
Università dell'Aquila, L'Aquila I-67100, Italy
Received for publication, July 25, 2001, and in revised form, September 17, 2001
 |
ABSTRACT |
Resistance to -lactam antibiotics mediated by
metallo- -lactamases is an increasingly worrying clinical problem.
Candidate inhibitors include mercaptocarboxylic acids, and we report
studies of a simple such compound, thiomandelic acid. A series of 35 analogues were synthesized and examined as metallo- -lactamase
inhibitors. The Ki values (Bacillus
cereus enzyme) are 0.09 µM for R-thiomandelic acid and 1.28 µM for the
S-isomer. Structure-activity relationships show that the
thiol is essential for activity and the carboxylate increases potency;
the affinity is greatest when these groups are close together.
Thioesters of thiomandelic acid are substrates for the enzyme,
liberating thiomandelic acid, suggesting a starting point for the
design of "pro-drugs." Importantly, thiomandelic acid is a broad
spectrum inhibitor of metallo- -lactamases, with a submicromolar
Ki value for all nine enzymes tested, except the
Aeromonas hydrophila enzyme; such a wide spectrum of activity is unprecedented. The binding of thiomandelic acid to the
B. cereus enzyme was studied by NMR; the results are
consistent with the idea that the inhibitor thiol binds to both zinc
ions, while its carboxylate binds to Arg91. Amide chemical
shift perturbations for residues 30-40 (the
3- 4 loop) suggest that this small
inhibitor induces a movement of this loop of the kind seen for other
larger inhibitors.
 |
INTRODUCTION |
The -lactam antibiotics are among the most useful antibacterial
chemotherapeutic agents, but their efficiency is being continuously challenged by the emergence of resistant strains of pathogenic bacteria. -Lactamases, which inactivate these antibiotics by hydrolyzing their endocyclic amide bond, play a major role in this
resistance (1). -Lactamases have been divided into four classes on
the basis of their amino acid sequences and catalytic mechanisms (2).
The mechanisms of class A, C, and D enzymes, which contain a
nucleophilic serine side chain as a key component of their active site,
have been extensively studied, due to their established clinical
importance. Class B enzymes are metalloproteins that require one or two
zinc ion(s) for their activity (3). The first metallo- -lactamase
(MBL)1 to be discovered was
produced by an innocuous strain of Bacillus cereus (4), but
in the last 20 years, MBL-mediated resistance has appeared in several
pathogenic strains including Bacteroides fragilis,
Aeromonas hydrophila, Stenotrophomonas maltophilia, and
Serratia marcescens (5). Even more threatening is the rapid dissemination of some metallo- -lactamase genes by horizontal transfer, involving both plasmid- and integron-borne genetic elements. For instance, the IMP enzymes that were first isolated in clinical isolates of S. marcescens and Pseudomonas
aeruginosa have also been found in Klebsiella,
Alcalinogenes, Acinetobacter, and
Shigella strains (6), and up to four variants of IMP-1 have
been described so far (7-10).
The MBLs with known sequences share a small number of conserved motifs,
but otherwise they show significant sequence diversity and have thus
been classified into three subclasses: subclass B1 includes BcII from
B. cereus (11, 12), CfiA (also called CcrA) from B. fragilis (13, 14), IMP-1 and VIM-1 from P. aeruginosa (6, 15), and BlaB from Chryseobacterium meningosepticum
(16); subclass B2 essentially consists of enzymes from
Aeromonas strains (e.g. CphA from A. hydrophila (17)); and subclass B3 includes the L1 enzyme from
Stenotrophomonas maltophilia (18, 19), along with FEZ-1 from
Legionella gormanii (20) and GOB-1 from C. meningosepticum (21). Crystal structures have been determined for
the B. cereus (11, 22), B. fragilis (13, 23, 24), and IMP-1 (25) enzymes, as well as for the subclass B3 enzyme from
S. maltophilia (26). These reveal a unique  /
"sandwich" topology characteristic of this family of enzymes,
distinct from other zinc enzymes such as thermolysin and
carboxypeptidase A.
Two zinc cations are present in the active site of the four MBLs for
which crystal structures are available (although in the case of the
B. cereus enzyme not in all reported structures); the zinc
ligands are not fully conserved between the different subclasses,
perhaps contributing to some of the observed differences in substrate
profiles and zinc affinities. Considering only the subclass B1 enzymes,
in site I the zinc is coordinated by the imidazole rings of three
histidine residues (His86, His88, and
His149 in the B. cereus enzyme;
His116, His118, and His196
according to the recently proposed standard numbering of MBLs (27)) and
one water molecule. In the structures with two zincs, this water (or
hydroxide) bridges to the zinc in site II, which is also coordinated by
a histidine (His210 in the B. cereus enzyme), a
cysteine, an aspartate, and a second water (or a carbonate ion). The
bridging water molecule is believed to be the nucleophile responsible
for lactam cleavage, but the precise role of the two metals in
catalysis is still unclear; mechanisms have been proposed in which only
site I plays a direct role in catalysis (28), or in which the two zinc
ions are both involved, as a binuclear center (3, 26, 29). Despite the conservation of all zinc ligands in this subclass, some enzymes (e.g. BcII (12, 30, 31)) seem to bind zinc rather loosely, whereas in other cases zinc is more difficult to remove and
reincorporate (14).2
Interestingly, whenever they have been prepared, mononuclear forms of
subclass B1 enzymes are active, and addition of the second zinc ion
usually results in only rather moderate increases of activity (12,
14).
Since MBLs are resistant to inactivators, such as clavulanic acid, of
the serine enzymes, the spread of MBL-mediated bacterial resistance to
-lactams (including carbapenems) is a matter of real concern. No
satisfactory inhibitors of MBLs are yet available for clinical use, and
the range of active site architectures for the MBLs makes the discovery
of useful broad spectrum inhibitors a challenging task. Work to date
allows the identification of at least five major groups of potential
MBL inhibitors. 1) Biphenyl tetrazoles are potent inhibitors of the
B. fragilis MBL, although they are much less active toward
other important MBLs such as IMP-1 (32); the crystal structure of a
complex between B. fragilis MBL and a biphenyl tetrazole
shows that the inhibitor binds to the zinc in site II, with the
displacement of a water molecule (32). 2) Some carbapenem derivatives
are potent inhibitors of several -lactamases including class B
enzymes (33), but they behave as poor substrates of MBLs and may be too
rapidly hydrolyzed by some of them to be effective therapeutic agents.
3) Inactivators of the A. hydrophila enzyme such as
trifluoromethyl alcohols and ketones (34) or hydroxamates (35) have
been described, but the mechanism of inhibition is still unclear, and
their activity against other MBLs is much lower. 4) Very recently,
succinic acid derivatives with aromatic substituents have been shown to
be potent inhibitors of the IMP-1 enzyme (36). 5) Thiol compounds as
simple as mercaptoacetic acid (37) can be potent inhibitors of MBLs, either as free thiols or in the protected form of a thioester (38). A
number of thiols (24, 28, 39, 40) and thioesters (41-43) have been
studied as inhibitors, but again, they often show activity only against
a restricted panel of MBLs. Crystal structures are available for the
complex of the IMP-1 enzyme with a potent mercaptocarboxylate substrate
analogue inhibitor (25), and NMR data are available for the binding of
other mercaptocarboxylate inhibitors to the MBLs from B. fragilis (40, 44) and B. cereus.3
We now report kinetic studies of the inhibition of MBLs by one of the
simplest potent mercaptocarboxylate inhibitors, thiomandelic acid (Fig.
1; -mercaptophenylacetic acid), and a number of analogues, together
with NMR studies of thiomandelic acid binding to the B. cereus MBL, BcII, as a starting point for the design of broad spectrum MBL inhibitors.
 |
EXPERIMENTAL PROCEDURES |
Chemicals and Syntheses--
4-Methoxyphenylacetic acid
(1b), 4-nitrophenylacetic acid (1c),
-bromophenylacetic acid (2a), 4-mercaptobenzoic acid
(9), and 2-thiophenecarboxylic acid (10) were purchased from Aldrich. 4-Fluorophenylacetic acid (1d) and
thiosalicylic acid (8) were from Acros Organics, and benzylmercaptan (11) was from Fluka. Compounds
7a-c and g-h (Fig. 1) were generous gifts from
Jean-Luc Boucher (CNRS, University Paris V) and were synthesized
according to Eloy and Lenaers (45). Thiomandelic acid and a series of
para-substituted analogues were synthesized in racemic form
by a modified version of the procedure described by Bonner (46).
Starting from the readily accessible appropriate -bromobenzeneacetic
acids 2b-d and commercially available 2a,
compounds 3a-d were synthesized by reaction with potassium
o-ethyldithiocarbonate, and 3aa-ab were
synthesized with the corresponding cesium salt. The
o-ethyldithiocarbonate group was then converted into a thiol
moiety via basic hydrolysis using concentrated ammonia in ethyl
alcohol. The -mercaptophenylacetic acids 4a-b, d were
obtained as a mixture with the corresponding disulfide derivatives 5a-b, d, whereas the nitro derivative 3c gave
only undesired side products. The oxidation of the thiol groups by using catalytic ferric chloride and sodium iodide (47) led to pure
(>95% by 1H NMR analysis) disulfides 5a-b, d.
The disulfide moiety is often a convenient protecting group, and thiols
are easily obtained by the reduction of disulfides. Here, compounds
5a-b, d were reduced with sodium borohydride to
give pure (>95% by 1H NMR analysis) thiols 4a-b,
d. The individual optical isomers, R- and
S-thiomandelic acids (15a and 15b), were synthesized by the procedure of Strijtveen and Kellog (48). The
ethyl esters 12a and 12b were prepared from the
commercially available S- and R-mandelic acids.
Methanesulfonates 13a and 13b were then obtained
by reacting methanesulfonyl chloride with 12a and
12b, respectively. Reaction of these mesylate derivatives
with the cesium salt of thioacetic acid led to the thioesters
14a and 14b, which were hydrolyzed. However,
after 4 days in concentrated hydrochloric acid at room temperature,
only starting material was recovered. Hydrolysis was thus carried out
at 50 °C for 12 h to give the desired compounds 15a
and 15b in an optical purity of 73-74%. Details of the
synthesis and characterization of individual compounds are given in the
Supplemental Material.
Enzyme Preparation--
All the MBLs used here were purified as
described in the following references: BcII (12), CfiA (23), L1 (26),
IMP-1 (6), IMP-2 (7), VIM-1 (15), BlaB (16), FEZ-1 (20), and CphA (17).
2H,15N-Labeled BcII for NMR spectroscopy was
prepared as described previously (49). For the cysteine 158 to alanine
mutant of IMP-1 (C158A), the pET9a construct bearing the entire
blaIMP gene (6) was used as a template for PCR
amplification with the following overlapping primers:
5'-GTACGGTTTAATAAATGCACCACCGAATAATATTTTCC-3' and
5'-GGAAAATATTATTCGGTGGTGCATTTATTAAACCGTAC-3'. The C158A
enzyme was produced and purified as for the wild-type enzyme (6).
Enzyme Kinetics--
Determinations of catalytic activity were
performed in 10 mM HEPES, pH 7.5, at 30 °C using a
Uvikon XL (Bio-tek instruments) spectrophotometer equipped with
thermostatically controlled cells. Substrate hydrolysis was followed by
monitoring the change in absorbance at the appropriate wavelength
(nitrocefin for BcII, CfiA, L1, IMP-1, and FEZ-1,  482 = 17,500 M 1 cm 1; imipenem for
IMP-2, BlaB, and CphA,  300 = 9000
M 1 cm 1; meropenem for VIM-1,
 297 = 6500 M 1
cm 1), and the substrate concentrations used were chosen
to be close to the Km value. For the screening of
potential inhibitors, nitrocefin (20 µM) was used as a
substrate, and the experiments were carried out at a final enzyme
(BcII) concentration of 4.8 nM. The compounds to be tested
were dissolved in ethanol at a concentration of 0.1 M and
then diluted to 1 mM in the enzyme assay. The presence of
1% ethanol proved to be without effect on the BcII activity (data not
shown). Quoted Ki values are derived assuming a
competitive pattern of inhibition and plotting v0/vi = f([I]),
where v0 is the initial rate in the absence of
inhibitor, and vi is the initial rate in the
presence of inhibitor. The slope of the resulting straight line is then given by Km/((Km + [S])·Ki). The specific activity toward the
thioesters 3aa and 3ab was also determined
spectrophotometrically in the presence of 4,4'-dithiodipyridine (Sigma), a sensitive thiol-specific reagent that has an absorption maximum at 324 nm ( = 19,800 M 1
cm 1) after reaction with two equivalents of thiol (50).
Incubations contained 1 mM thioester, 2.5 mM
4,4'-dithiodipyridine (0.1 M stock solutions of both
compounds prepared in ethanol) and 0.6 µM BcII in 500 µl of 10 mM HEPES, pH 7.5. Subtraction of the side reaction due to the nonenzymatic release of thiol from the thioester in
the presence of 4,4'-dithiodipyridine was performed by using a double
beam spectrophotometer in which the reference cuvette contained
thioester and 4,4'-dithiodipyridine at the same concentration as in the
sample cuvette but no enzyme. Control experiments with nitrocefin as
substrate demonstrated that the presence of 4,4'-dithiodipyridine at
the concentration used did not inhibit the catalytic activity of the enzyme.
Protein NMR Spectroscopy--
Samples of the inhibitor complexes
of the BCII enzyme for NMR spectroscopy were prepared by the addition
of microliter volumes of stock inhibitor solution (50 mM in
0.2 M MES buffer, pH 6.4) to a solution of 1.0 mM 15N-labeled enzyme in the same
buffer. Spectra were acquired at 298 K using Bruker DMX 500-MHz or DRX
600-MHz spectrometers equipped with 5-mm inverse detection triple
resonance probes with z axis gradient. Backbone amide NH
resonances were observed using the 1H-15N HSQC
experiment with gradient coherence selection and sensitivity enhancement (51). The assignment of these resonances by means of triple
resonance experiments using
2H,13C,15N-labeled enzyme is
described elsewhere.3 The effects of inhibitor binding on
the amide resonances were analyzed as follows. For each cross-peak in
the 1H-15N HSQC spectrum of the free protein,
the nearest cross-peak (in terms of 1H and 15N
chemical shifts) in the spectrum of the inhibitor complex was identified. The 1H and 15N chemical shift
differences, H and N, between each such pair of cross-peaks were
measured and used to calculate a "minimum shift index" (52).
|
(Eq. 1)
|
One-dimensional 1H spectra of histidine imidazole
(N)H protons were obtained by using the Watergate experiment with water flipback pulse (53, 54); 1H-15N correlation
spectra of the histidine imidazole resonances were obtained using
1H-15N HMQC as previously described (49).
Spectra were processed using UXNMR (Bruker) software.
 |
RESULTS AND DISCUSSION |
In view of the evidence, discussed above, that simple thiol
compounds and mercaptoacetic acid thiol esters are inhibitors of MBLs
and that the most effective compounds contain both thiol and
carboxylate groups, we have investigated the inhibition of MBLs by
thiomandelic acid ( -mercaptophenylacetic acid) and a number of
structurally related compounds. Thiomandelic acid and a series of
para-substituted analogues were synthesized in racemic form
by a modified version of the method described by Bonner (46), and the
individual optical isomers, R- and S-thiomandelic
acids (15a and 15b), were prepared by the
procedure of Strijtveen and Kellog (48).
Screening for MBL Inhibition--
Racemic thiomandelic acid
(4a) and a number of analogues and synthetic intermediates
(Fig. 1) were initially screened for
inhibitory activity against B. cereus MBL (BcII) by
measuring the residual activity against nitrocefin in the presence of
each compound at a concentration of 1 mM. The results are
presented in Fig. 2 and show that 10 of
the 35 compounds tested inhibit BcII by >50% under these conditions.
Comparison of the residual activity in the presence of compounds
4a-b, d (thiomandelic acid and para-substituted
analogues) with that for compounds 1a-d (lacking the SH)
and 11 (lacking the COOH) shows that the thiol group is
essential for inhibition but the carboxylate group is not, although it
leads to a significant increase in potency. Replacement of the thiol by
a hydroxyl (6a-b, d-f), bromo (2a-d), or
amidoxime (7a-c, g-h) function effectively abolishes
inhibitory activity. Amidoximes 7a-c, g-h were also
inactive toward CphA, despite their resemblance to previously described
hydroxamate inhibitors of this enzyme (35). Protection of the thiol as
thioncarboethoxy (3a-d), thioester (3aa-ab) or
disulfide (5a-b, d) derivatives is detrimental, but some
inhibitory activity is retained for compounds 3c, 3aa-ab and
5a-b, d. Altogether, these preliminary results clearly demonstrate that the thiol group plays a major role in the interaction between MBLs and derivatives of mandelic acid.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 1.
Structures of thiomandelic acid and related
compounds studied as inhibitors of
metallo- -lactamases.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 2.
Comparison of the activity of the BcII enzyme
in the absence (control) or presence of 1 mM
concentrations of the compounds shown in Fig. 1. Activity
was measured with nitrocefin as substrate, as described under
"Experimental Procedures," and corresponds to 400 nmol/s/mg in the
absence of inhibitor (C).
|
|
Inhibition constants were determined for those compounds exhibiting
more than 50% inhibition at 1 mM (Fig. 2), and these are presented in Table I. The most potent
inhibitors are thiomandelic acid itself and the two
para-substituted analogues (4a, b, d), with
Ki values of 0.2-0.5 µM as the
racemates. The nature of the para substituent had little
effect on the inhibition constant, suggesting that this group does not
make specific interactions with the active site. Comparison of the
relative potencies of compounds 4a, 8, and
9 shows that the affinity for BcII is greatest when the
thiol and carboxylate groups are in close spatial proximity. Of these
two groups, the thiol is clearly the major driving force for binding,
since its replacement even by a hydroxyl group completely abolishes
activity (6a, Fig. 2), whereas removal of the carboxylate
group increases Ki by only ~30-fold (4a
versus 11, Table I).
View this table:
[in this window]
[in a new window]
|
Table I
Inhibition constants of some thiomandelic acid derivatives for the B. cereus metallo- -lactamase (BcII)
Ki values are calculated assuming a competitive
pattern of inhibition. Mean values of at least two separate experiments
are shown (S.D. < 20%).
|
|
The Ki values of the disulfide (5a) and
thioesters (3aa-ab) of thiomandelic acid are 100-fold
higher than those of the thiol compound, and we cannot rule out the
possibility that the inhibitory activity observed in these cases is due
to the generation of small amounts of thiols. The possible generation of thiomandelic acid by enzyme-catalyzed hydrolysis of the thioesters was investigated by using 4,4'-dithiodipyridine (50) to measure thiol
formation. This possibility is also of interest in considering the
potential of thioesters as "pro-drugs" for in vivo use.
The increase in absorbance at 324 nm characteristic of the reaction of
4,4'-dithiodipyridine with thiols was found to be
time-dependent, substrate-dependent, and
enzyme-dependent for both 3aa and
3ab; subtraction of the nonenzymatic rate revealed clear
catalysis of the hydrolysis of these thioesters by BcII. An attempt was
made to determine the Km and
Vmax values for this reaction, but product
inhibition (presumably by thiomandelic acid) was too great to reach
substrate saturation. At 1 mM substrate concentrations, the
specific activity of BcII was found to be 424 ± 55 nmol/min/mg
(0.18 ± 0.02 s 1) versus 3aa
and 460 ± 60 nmol/min/mg (0.18 ± 0.02 s 1)
versus 3ab. This activity is low compared with
the usual activities of MBLs against -lactams, and the classical
competitive inhibition model used here should not be perturbed at the
thioester and enzyme concentrations required to measure the
Ki values in Table I. Thus, the amount of
thiomandelic acid generated during the incubation will be much too low
to account for the observed inhibition, which must be due to the
thioesters themselves. In such conditions, to a good approximation,
Km = Ki for 3aa and
3ab, but the corresponding kcat
cannot be determined.
Thiomandelic Acid Is a Broad Spectrum MBL Inhibitor--
In light
of these observations, thiomandelic acid was chosen for more detailed
investigation. We determined the inhibitory activity of the racemic
compound against most of the MBLs currently available (Table
II). Thiomandelic acid was found to be a
reasonably potent (submicromolar) inhibitor for all of the MBLs tested,
except for the subclass B2 enzyme from A. hydrophila (CphA).
Such a wide spectrum of activity against MBLs of subclasses B1 and B3
is unprecedented in previously published data concerning MBL
inhibitors. For instance, thiomandelic acid is only about 25-fold less
potent as an inhibitor of the CfiA (CcrA) enzyme from B. fragilis than of the IMP-1 enzyme from P. aeruginosa.
This is in marked contrast to the reported thioester MBL inhibitors,
which are very much poorer inhibitors of the B. fragilis
enzyme (38, 41, 43).
Characteristics of Inhibition by Thiomandelic Acid--
Synthesis
and analysis of the individual stereoisomers showed that the
stereochemistry at the -carbon has a modest effect on the binding of
thiomandelic acid to the BcII enzyme, the Ki of
R-thiomandelic acid (15a) being 14-fold less than
that of the S-isomer (15b) (Table I).
The kinetic data for thiomandelic acid fitted a competitive pattern of
inhibition, and no evidence was obtained for irreversible binding of
thiomandelic acid to the BcII enzyme. Preincubation of the enzyme with
thiomandelic acid for 30 min at 30 °C did not modify the degree of
inhibition. Although the time dependence of the activity was not linear
over the first few minutes (suggesting that a two-step process may
occur), the inhibition was fully and quickly reversible upon dilution
or upon the addition of excess zinc (which binds free thiomandelic
acid). Mass spectrometry of the enzyme after incubation with
thiomandelic acid gave no evidence for a covalent adduct.
To investigate the possibility that thiomandelic acid might form a
disulfide bridge with the cysteine involved in zinc binding (the only
cysteine residue conserved in all of the zinc -lactamases), as
demonstrated earlier for mercaptoacetic acid thioesters (38), we
examined thiomandelic acid inhibition of the C158A mutant of IMP-1. The
Ki value of thiomandelic acid for this mutant was
found to be 1.83 µM, 63-fold greater than that for the
wild-type enzyme but still indicating significant inhibition. This
higher Ki may reflect the much weaker binding of the
second zinc to this mutant. A much greater loss of potency would have been expected if cysteine 158 had been directly involved in the inhibitory process. It is possible that the disulfide bond formation previously observed (38) results from slow adventitious oxidation, which is not relevant on the time scale of our kinetic analyses.
NMR Spectroscopy--
To obtain direct information on the binding
of thiomandelic acid to the BcII enzyme, its effects on the backbone
and imidazole NH resonances of the enzyme were investigated.
Effect of Inhibitors on the Imidazole Resonances of the Metal
Ligands--
The imidazole resonances of the metal-binding histidine
residues (His86, His88, and His149
in site I, His210 in site II), which have been assigned to
individual residues (49),3 provide valuable probes of the
effects of inhibitors on the active site. The imidazole NH resonances
appear between 12 and 15 ppm (Fig. 3). In
the absence of inhibitors at pH 6.4, 298 K, relatively sharp resonances
are observed for His86 and His88 and a broad
resonance for His210, but no signal is apparent for
His149. At lower pH or temperature, the His210
resonance sharpens, and a signal for His149 appears. These
differences in line width reflect the differences in accessibility of
the histidine imidazole NHs for exchange with the solvent. The gradual
addition of either R- or S-thiomandelic acid to
the enzyme resulted in a progressive decrease in the intensity of the
imidazole NH signals from the free enzyme and a progressive increase in
a new set of signals attributable to the enzyme-inhibitor complex. The
changes were complete at a 1:1 ratio of inhibitor to enzyme. The
spectra of the BcII-R-thiomandelic acid and
BcII-S-thiomandelic acid complexes are shown in Fig. 3. The
imidazole NH resonances of these complexes were assigned by using
1H-15N HMQC spectra optimized for observation
of the long range 1H-15N couplings in the
imidazole ring (49) (see "Supplemental Material"). These spectra
allow one to connect the NH resonances to those of the two nitrogens
and the two CH protons in each imidazole. Whereas there are
changes in 15N and CH chemical shift on inhibitor binding,
the pattern of connectivities in the HMQC spectrum permits the
assignment of the imidazole resonances in the spectrum of the
R- and S-thiomandelic acid complexes by comparison with the spectrum of the free enzyme, and the chemical shifts are summarized in Table III.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Part of the 1H NMR spectrum of
BcII in the presence and absence of R- and
S-thiomandelic acid, showing the imidazole NH
resonances of the metal-binding histidine residues.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
1H and 15N chemical shifts of the imidazole rings of
the metal-binding histidine residues of BcII in the presence and
absence of R- and S-thiomandelic acid
|
|
It is clear that the imidazoles in both metal binding sites are
markedly affected by inhibitor binding. In site I, both
His86 and His88 show large (>0.5 ppm) changes
in NH chemical shift on inhibitor binding, upfield for
His88 and downfield for His86, the shifts being
somewhat greater for the S- than the R-isomer. The C H proton resonance of His86 also shows a striking
downfield shift of >2 ppm on inhibitor binding. The resonances of the
unprotonated imidazole nitrogen (the zinc ligand; N for
His86 and His149, N for His88)
of the histidines in site I show large downfield shifts (up to ~9
ppm); for His88 and His149, but not
His86, these are larger with the S-isomer than
with the R-isomer. In site II, by contrast, the N (zinc
ligand) resonance of His210 shows a large downfield shift
on binding R-thiomandelic acid but a large upfield shift on
binding the S-isomer. In the case of the cadmium-substituted
BcII enzyme, 113Cd NMR has provided strong evidence for the
binding of the sulfur atom of R-thiomandelic acid to both
the metal ions in the active site,3 presumably displacing
the "bridging" water molecule, as seen for a much more complex
thiocarboxylate inhibitor bound to the IMP-1 enzyme (25). The present
data for the zinc BcII enzyme are entirely consistent with this mode of
binding of thiomandelic acid. The different shifts seen for the
resonances of the histidines in sites I and II for the R-
and S-isomers of the inhibitor, which presumably reflect
differences in electron distribution on the metal ligands, may
represent a slightly different position of the sulfur atom between the
two zinc atoms imposed by the interactions of the rest of the molecule
with the enzyme.
A second clear difference between the complexes of the enzyme with the
two isomers of thiomandelic acid is in the line width of the imidazole
NH resonance of His149. Inhibitor binding clearly tends to
decrease the rate of exchange with water of the imidazole NHs of the
metal-binding histidines, thus sharpening their resonances, but the
magnitude of this effect varies significantly from one residue to
another. For example, the resonances of His86 and
His88 are reasonably sharp in the spectrum of the free
enzyme and their line widths are little affected by inhibitor binding,
whereas the resonance of His210 is broad in the spectrum of
the free enzyme and is markedly sharpened, to approximately the same
extent, by the binding of either R- or
S-thiomandelic acid. The NH resonance of His149,
on the other hand, is too broad to see in the spectrum of the free
enzyme and also in that of the S-thiomandelic acid complex; only the binding of the R-isomer of the inhibitor decreases
the imidazole NH exchange rate of this residue sufficiently to yield an
observable resonance, in fact one as sharp as those of the other three
active site histidines in this complex (Fig. 3).
Effect of Inhibitor Binding on the Backbone Amide
Resonances--
A two-dimensional proton-nitrogen correlation
spectrum (1H-15N HSQC) of
15N-labeled BcII allows the rapid observation of most of
the backbone amide 1H and 15N resonances. These
resonances have been assigned to individual residues in the free
protein,3 and monitoring changes in these resonances thus
provides a convenient method for identifying the regions of the enzyme
affected by inhibitor binding.
Fig. 4 shows a comparison of the
1H-15N HSQC spectra of the free enzyme and of
the enzyme in the presence of S-thiomandelic acid. Most of
the spectrum remains essentially unaffected, but some significant
changes are observed, generally involving residues that are close to
the zinc binding sites. Only very few residues in the secondary
structure elements of the core of the protein seemed to be affected by
the inhibitor; some 90 residues in this part of the structure that give
resolved resonance signals were unaffected by the addition of
inhibitors. Whereas the resonance assignment for the free enzyme is
complete, the resonances in the complex are not yet assigned, so that
the magnitude of the shifts of individual resonances cannot be
accurately determined. We have thus used the "minimum chemical
shift" approach (52, 55, 56), in which the chemical shift difference
from a given cross-peak in the free protein to the closest cross-peak
in the complex is calculated, as described under "Experimental
Procedures." Whereas this method can of course lead to
underestimation of chemical shift changes, particularly in crowded
regions of the spectrum, it can provide a reliable identification of
the interaction site(s) (56, 57). The "minimum chemical shift
index" (Ref. 52; see "Experimental Procedures") is plotted as a
function of residue number for both the R- and
S-thiomandelic acid complexes in Fig. 5, and the residues showing the greatest
shifts are mapped on to the structure of the enzyme in Fig.
6.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
1H-15N HSQC spectra
of BcII in the presence and absence of S-thiomandelic
acid, showing the backbone and side chain amide and tryptophan indole
NH resonances. The cross-peaks are shown in black for
the spectrum of the enzyme alone and in red for that of the
S-thiomandelic acid complex. Resonance
assignments3 are indicated for a number of the better
resolved signals that are affected by inhibitor binding.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
The changes in chemical shift of the amide
resonances of BcII on the binding of R- thiomandelic
acid (solid bars) or
S-thiomandelic acid (open
bars). As discussed under "Results and
Discussion," the changes are expressed as the "minimum
chemical shift index," calculated as described under "Experimental
Procedures."
|
|

View larger version (74K):
[in this window]
[in a new window]
|
Fig. 6.
Ribbon diagram of the structure of BcII.
The residues whose amide resonances are most affected by the binding of
S-thiomandelic acid are indicated in red on the
backbone ribbon; side chains are shown for the zinc ligands and
some other residues mentioned under "Results and Discussion."
|
|
A notable feature of the chemical shift changes on complex formation is
the strong qualitative similarity in the effects of R- and
S-thiomandelic acid; it is clear from Fig. 5 that, with few
exceptions, the same residues are affected by the binding of both
isomers. The amide resonances of the zinc binding residues Asp90, His88, His86,
His149, and Cys168 are all clearly affected;
that of His210 is in a crowded region of the spectrum and
cannot be followed with certainty. For several of the residues in the
active site, including the zinc ligands His88 and
His149, as well as the nearby residues Ile84,
Asp152, and Gly167, the changes in the shift
index are greater in the S- than in the
R-thiomandelic acid complex; the only exception is
Gly211, which is affected more by the
R-isomer.
The largest change in amide chemical shift on inhibitor binding is seen
for Arg91, which is affected to a very similar extent by
both isomers of thiomandelic acid. This suggests the possibility that
the guanidino group of this residue might be responsible for
interacting with the carboxylate group of the inhibitor. This residue
does not correspond to the residue Lys161, which binds the
inhibitor carboxylate in the complex of the IMP-1 enzyme with a
mercaptocarboxylate (25), but the relationship between the thiol and
the carboxylate of this inhibitor is quite different from that in
thiomandelic acid. It must be noted, however, that the guanidino group
of Arg91 in BcII is close to the two zinc binding sites and
hydrogen-bonds to the zinc ligand Asp90; we cannot,
therefore, exclude the possibility that the effects of thiomandelic
acid binding on this residue are secondary to the thiol binding to the
metal ions nor indeed that the carboxylate also interacts with one of
the zincs, as seen in the recent structures of substituted succinic
acid derivatives with the IMP-1 enzyme (36).
Substantial amide chemical shift perturbations are also observed for
residues in the "flexible flap" region (the
3- 4 loop, residues 30-40), which in the
absence of inhibitor is some distance from the active site (Fig. 6).
Shift changes are seen for Glu30, Leu31,
Phe34, and Val39. (A significant chemical shift
perturbation was also observed for Trp59, which is located
at the beginning of a loop on the top of the cavity; since the side
chain of Trp59 extends toward the
3- 4 loop (see Fig. 6), this could
result from a movement of the latter). Chemical shift effects on
residues in the corresponding loop or -hairpin were noted by
Scrofani et al. (40) in their studies of a tightly binding
inhibitor of the B. fragilis MBL. Crystallographic studies
of inhibitor binding to the IMP-1 MBL (25) clearly show that, upon the
binding of a rather large mercaptocarboxylate inhibitor, the
corresponding loop or -hairpin folds over the active site, making
important contacts with the bound inhibitor. The evidence described
here on the B. cereus enzyme, together with the chemical
shift and relaxation studies of inhibitor binding to the B. fragilis enzyme (40, 44), strongly suggests that a movement of
this loop is a general and important feature of inhibitor binding to
MBLs. It is particularly interesting that the loop movement apparently takes place even on the binding of an inhibitor as small as
thiomandelic acid, suggesting the possibility that the trigger for this
movement is conformational, rather than simply arising from direct
interactions of loop residues with the inhibitor. The linkage of the
relatively distant loop movement with inhibitor binding may have
mechanistic relevance. Thus, the loop may be involved in substrate
capture and help to direct the -lactam of the substrate toward the
metal center; in turn, the hydrolytic chemistry at the metal center may
be coordinated with product release through movement of this loop.
Conclusions--
The data presented here demonstrate that the
simple molecule thiomandelic acid is a reasonably potent and broad
spectrum inhibitor of metallo- -lactamases. This report is the first
demonstration that broad spectrum inhibition of MBLs is feasible. The
data are consistent with the idea that both R- and
S-thiomandelic acid bind in such a way that the thiol group
of the inhibitor binds to the two zinc atoms in the active site. The
chemical shift changes suggest that the carboxylate group of the
inhibitor may bind to Arg91, a well conserved residue in
subclass B1 enzymes, and this appears to be the case for both optical
isomers of the inhibitor, since both produce similar effects on the
amide resonance of this residue. The structure-activity relationship
among the thiomandelic acid analogues studied here indicates that the
carboxylate and, particularly, the thiol groups are most important for
binding, and the conclusion that these two groups bind similarly to the
enzyme in both R- and S-thiomandelic acid is
consistent with the finding that there is a relatively modest
difference in Ki between the two isomers. Similar
binding of the thiol and carboxylate groups would imply that the phenyl
ring of the two isomers binds in a different position in the active
site. The modest observed difference in Ki would
then indicate that this phenyl ring does not contribute to binding in a
major way, again consistent with the structure-activity relationships.
The different positions of the phenyl rings of R- and
S-thiomandelic acid in the active site are likely to
contribute to the different effects of the two compounds on the
chemical shifts of residues in the active site, both directly, through the magnetic anisotropy of the phenyl ring itself, and indirectly, through its interactions with the protein, which may lead
to slight differences in position of the thiol and carboxylate groups
of the inhibitor. The 3- 4 loop, or
"flap," is clearly affected even by the binding of this small
inhibitor, confirming its role as an important determinant of ligand
binding in subclass B1 enzymes. Finally, the observation that
thioesters of thiomandelic acid, themselves rather weak inhibitors, are
hydrolyzed by the enzyme to yield the much more inhibitory thiomandelic
acid suggests that these compounds should be valuable alternatives for
in vivo use and deserve further study.
 |
ACKNOWLEDGEMENT |
We thank Jean-Luc Boucher (CNRS, Paris) for
kindly providing some of the compounds analyzed here.
 |
FOOTNOTES |
*
This work was supported by the European research network on
metallo- -lactamases, within the Training and Mobility of Researchers program (contract ERBFMRXCT 980232), by the Wellcome Trust (Traveling Research Fellowship to C. F. D.), by the Biotechnology and Biological Sciences Research Council, and by the Belgian program Pôles
d'Attraction Interuniversitaire Grant PAI P4/03.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains two schemes and one figure.
§
These authors contributed equally to this work.

To whom correspondence should be addressed. Tel.:
44-116-252-2978; Fax: 44-116-223-1503; E-mail: gcr@le.ac.uk.
Published, JBC Papers in Press, September 19, 2001, DOI 10.1074/jbc.M107054200
2
C. Moali, unpublished results obtained with
IMP-1.
3
C. F. Damblon, I. G. Barsukov, C. Mollard, and G. C. K. Roberts, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
MBL, metallo- -lactamase;
BcII, the zinc metallo- -lactamase
from B. cereus;
HSQC, heteronuclear single quantum
coherence;
HMQC, heteronuclear multiple quantum coherence;
MES, 2-[N-morpholino]ethanesulfonic acid.
 |
REFERENCES |
| 1.
|
Frère, J. M.
(1995)
Mol. Microbiol.
16,
385-395
|
| 2.
|
Matagne, A.,
Dubus, A.,
Galleni, M.,
and Frère, J. M.
(1999)
Nat. Prod. Rep.
16,
1-19
|
| 3.
|
Wang, Z.,
Fast, W.,
Valentine, A. M.,
and Benkovic, S. J.
(1999)
Curr. Opin. Chem. Biol.
3,
614-622
|
| 4.
|
Kuwabara, S.,
and Abraham, E. P.
(1967)
Biochem. J.
103,
27C-30C
|
| 5.
|
Payne, D. J.
(1993)
J. Med. Microbiol.
39,
93-99
|
| 6.
|
Laraki, N.,
Franceschini, N.,
Rossolini, G. M.,
Santucci, P.,
Meunier, C.,
de Pauw, E.,
Amicosante, G.,
Frère, J. M.,
and Galleni, M.
(1999)
Antimicrob. Agents Chemother.
43,
902-906
|
| 7.
|
Riccio, M. L.,
Franceschini, N.,
Boschi, L.,
Caravelli, B.,
Cornaglia, G.,
Fontana, R.,
Amicosante, G.,
and Rossolini, G. M.
(2000)
Antimicrob. Agents Chemother.
44,
1229-1235
|
| 8.
|
Iyobe, S.,
Kusadokoro, H.,
Ozaki, J.,
Matsumura, N.,
Minami, S.,
Haruta, S.,
Sawai, T.,
and O'Hara, K.
(2000)
Antimicrob. Agents Chemother.
44,
2023-2027
|
| 9.
|
Chu, Y. W.,
Afzal-Shah, M.,
Houang, E. T.,
Palepou, M. F.,
Lyon, D. J.,
Woodford, N.,
and Livermore, D. M.
(2001)
Antimicrob. Agents Chemother.
45,
710-714
|
| 10.
|
Yano, H.,
Kuga, A.,
Okamoto, R.,
Kitasato, H.,
Kobayashi, T.,
and Inoue, M.
(2001)
Antimicrob. Agents Chemother.
45,
1343-1348
|
| 11.
|
Fabiane, S. M.,
Sohi, M. K.,
Wan, T.,
Payne, D. J.,
Bateson, J. H.,
Mitchell, T.,
and Sutton, B. J.
(1998)
Biochemistry
37,
12404-12411
|
| 12.
|
Paul-Soto, R.,
Bauer, R.,
Frère, J. M.,
Galleni, M.,
Meyer-Klaucke, W.,
Nolting, H.,
Rossolini, G. M.,
de Seny, D.,
Hernandez-Valladares, M.,
Zeppezauer, M.,
and Adolph, H. W.
(1999)
J. Biol. Chem.
274,
13242-13249
|
| 13.
|
Concha, N. O.,
Rasmussen, B. A.,
Bush, K.,
and Herzberg, O.
(1996)
Structure
4,
823-836
|
| 14.
|
Paul-Soto, R.,
Hernadez-Valladares, M.,
Galleni, M.,
Bauer, R.,
Zeppezauer, M.,
Frère, J. M.,
and Adolph, H. W.
(1998)
FEBS Lett.
438,
137-140
|
| 15.
|
Franceschini, N.,
Caravelli, B.,
Docquier, J. D.,
Galleni, M.,
Frère, J. M.,
Amicosante, G.,
and Rossolini, G. M.
(2000)
Antimicrob. Agents Chemother.
44,
3003-3007
|
| 16.
|
Rossolini, G. M.,
Franceschini, N.,
Riccio, M. L.,
Mercuri, P. S.,
Perilli, M.,
Galleni, M.,
Frère, J. M.,
and Amicosante, G.
(1998)
Biochem. J.
332,
145-152
|
| 17.
|
Hernandez Valladares, M.,
Felici, A.,
Weber, G.,
Adolph, H. W.,
Zeppezauer, M.,
Rossolini, G. M.,
Amicosante, G.,
Frère, J. M.,
and Galleni, M.
(1997)
Biochemistry
36,
11534-11541
|
| 18.
|
Walsh, T. R.,
Hall, L.,
Assinder, S. J.,
Nichols, W. W.,
Cartwright, S. J.,
MacGowan, A. P.,
and Bennett, P. M.
(1994)
Biochim. Biophys. Acta
1218,
199-201
|
| 19.
|
Crowder, M. W.,
Walsh, T. R.,
Banovic, L.,
Pettit, M.,
and Spencer, J.
(1998)
Antimicrob. Agents Chemother.
42,
921-926
|
| 20.
|
Mercuri, P. S.,
Bouillenne, F.,
Boschi, L.,
Lamotte-Brasseur, J.,
Amicosante, G.,
Devreese, B.,
Van Beeumen, J.,
Frère, J. M.,
Rossolini, G. M.,
and Galleni, M.
(2001)
Antimicrob. Agents Chemother.
45,
921-926
|
| 21.
|
Bellais, S.,
Aubert, D.,
Naas, T.,
and Nordmann, P.
(2000)
Antimicrob. Agents Chemother.
44,
1878-1886
|
| 22.
|
Carfi, A.,
Duée, E.,
Galleni, M.,
Frère, J. M.,
and Dideberg, O.
(1998)
Acta Crystallogr. Sect. D Biol. Crystallogr.
54,
313-323
|
| 23.
|
Carfi, A.,
Duée, E.,
Paul-Soto, R.,
Galleni, M.,
Frere, J. M.,
and Dideberg, O.
(1998)
Acta Crystallogr. Sect. D Biol. Crystallogr.
54,
45-57
|
| 24.
|
Fitzgerald, P. M.,
Wu, J. K.,
and Toney, J. H.
(1998)
Biochemistry
37,
6791-6800
|
| 25.
|
Concha, N. O.,
Janson, C. A.,
Rowling, P.,
Pearson, S.,
Cheever, C. A.,
Clarke, B. P.,
Lewis, C.,
Galleni, M.,
Frère, J. M.,
Payne, D. J.,
Bateson, J. H.,
and Abdel-Meguid, S. S.
(2000)
Biochemistry
39,
4288-4298
|
| 26.
|
Ullah, J. H.,
Walsh, T. R.,
Taylor, I. A.,
Emery, D. C.,
Verma, C. S.,
Gamblin, S. J.,
and Spencer, J.
(1998)
J. Mol. Biol.
284,
125-136
|
| 27.
|
Galleni, M.,
Lamotte-Brasseur, J.,
Rossolini, G. M.,
Spencer, J.,
Dideberg, O.,
and Frère, J. M.
(2001)
Antimicrob. Agents Chemother.
45,
660-663
|
| 28.
|
Bounaga, S.,
Laws, A. P.,
Galleni, M.,
and Page, M. I.
(1998)
Biochem. J.
331,
703-711
|
| 29.
|
Wang, Z. G.,
Fast, W.,
and Benkovic, S. J.
(1999)
Biochemistry
38,
10013-10023
|
| 30.
|
Baldwin, G. S.,
Galdes, A.,
Hill, H. A.,
Waley, S. G.,
and Abraham, E. P.
(1980)
J. Inorg. Biochem.
13,
189-204
|
| 31.
|
Orellano, E. G.,
Girardini, J. E.,
Cricco, J. A.,
Ceccarelli, E. A.,
and Vila, A. J.
(1998)
Biochemistry
37,
10173-10180
|
| 32.
|
Toney, J. H.,
Fitzgerald, P. M.,
Grover-Sharma, N.,
Olson, S. H.,
May, W. J.,
Sundelof, J. G.,
Vanderwall, D. E.,
Cleary, K. A.,
Grant, S. K.,
Wu, J. K.,
Kozarich, J. W.,
Pompliano, D. L.,
and Hammond, G. G.
(1998)
Chem. Biol.
5,
185-196
|
| 33.
|
Nagano, R.,
Adachi, Y.,
Imamura, H.,
Yamada, K.,
Hashizume, T.,
and Morishima, H.
(1999)
Antimicrob. Agents Chemother.
43,
2497-2503
|
| 34.
|
Walter, M. W.,
Felici, A.,
Galleni, M.,
Paul-Soto, R.,
Adlington, R. M.,
Baldwin, J. E.,
Frère, J. M.,
Gololobov, M.,
and Schofield, C. J.
(1996)
Bioorg. Med. Chem. Lett.
6,
2455-2458
|
| 35.
|
Walter, M. W.,
Hernandez Valladres, M.,
Adlington, R. M.,
Amicosante, G.,
Baldwin, J. E.,
Frère, J. M.,
Galleni, M.,
Rossolini, G. M.,
and Schofield, C. J.
(1999)
Bioorg. Chem.
27,
35-40
|
| 36.
|
Toney, J. H.,
Hammond, G. G.,
Fitzgerald, P. M. D.,
Sharma, N.,
Balkovec, J. M.,
Rouen, G. P.,
Olson, S. H.,
Hammond, M. L.,
Greenlee, M. L.,
and Gao, Y.-D.
(2001)
J. Biol. Chem.
276,
31913-31918
|
| 37.
|
Goto, M.,
Takahashi, T.,
Yamashita, F.,
Koreeda, A.,
Mori, H.,
Ohta, M.,
and Arakawa, Y.
(1997)
Biol. Pharm. Bull.
20,
1136-1140
|
| 38.
|
Payne, D. J.,
Bateson, J. H.,
Gasson, B. C.,
Proctor, D.,
Khushi, T.,
Farmer, T. H.,
Tolson, D. A.,
Bell, D.,
Skett, P. W.,
Marshall, A. C.,
Reid, R.,
Ghosez, L.,
Combret, Y.,
and Marchand-Brynaert, J.
(1997)
Antimicrob. Agents Chemother.
41,
135-140
|
| 39.
| Page, M. I., and Laws, A. P. (1998) Chem. Commun.
1609-1617
|
| 40.
|
Scrofani, S. D.,
Chung, J.,
Huntley, J. J.,
Benkovic, S. J.,
Wright, P. E.,
and Dyson, H. J.
(1999)
Biochemistry
38,
14507-14514
|
| 41.
|
Payne, D. J.,
Bateson, J. H.,
Gasson, B. C.,
Khushi, T.,
Proctor, D.,
Pearson, S. C.,
and Reid, R.
(1997)
FEMS Microbiol. Lett.
157,
171-175
|
| 42.
|
Greenlee, M. L.,
Laub, J. B.,
Balkovec, J. M.,
Hammond, M. L.,
Hammond, G. G.,
Pompliano, D. L.,
and Epstein-Toney, J. H.
(1999)
Bioorg. Med. Chem. Lett.
9,
2549-2554
|
| 43.
|
Hammond, G. G.,
Huber, J. L.,
Greenlee, M. L.,
Laub, J. B.,
Young, K.,
Silver, L. L.,
Balkovec, J. M.,
Pryor, K. D.,
Wu, J. K.,
Leiting, B.,
Pompliano, D. L.,
and Toney, J. H.
(1999)
FEMS Microbiol. Lett.
179,
289-296
|
| 44.
|
Huntley, J. J. A.,
Scrofani, S. D. B.,
Osborne, M. J.,
Wright, P. E.,
and Dyson, H. J.
(2000)
Biochemistry
39,
13356-13364
|
| 45.
|
Eloy, F.,
and Lenaers, R.
(1962)
Chem. Rev.
62,
155-183
|
| 46.
|
Bonner, W. A.
(1968)
J. Org. Chem.
33,
1831-1836
|
| 47.
|
Iranpoor, N.,
and Zeynizadeh, B.
(1999)
Synthesis
1,
49-50
|
| 48.
|
Strijtveen, B.,
and Kellog, R. M.
(1986)
J. Org. Chem.
51,
3664-3671
|
| 49.
|
Damblon, C.,
Prosperi, C.,
Lian, L. Y.,
Barsukov, I.,
Paul-Soto, R.,
Galleni, M.,
Frère, J. M.,
and Roberts, G. C. K.
(1999)
J. Am. Chem. Soc.
121,
11575-11576
|
| 50.
|
Grassetti, D. R.,
and Murray, J. F.
(1967)
Arch. Biochem. Biophys.
119,
41-49
|
| 51.
|
Kay, L. E.,
Keifer, P.,
and Saarinen, T.
(1992)
J. Am. Chem. Soc.
114,
10663-10665
|
| 52.
|
Lian, L.-Y.,
Barsukov, I.,
Golovanov, A.,
Hawkins, D.,
Sze, K.-H.,
Badii, R.,
Keep, N. H.,
and Roberts, G. C. K.
(2000)
Structure
8,
47-55
|
| 53.
|
Piotto, M.,
Saudek, V.,
and Sklenar, V.
(1992)
J. Biomol. NMR
2,
661-665
|
| 54.
|
Kuboniwa, H.,
Grzesiek, S.,
Delaglio, F.,
and Bax, A.
(1994)
J. Biomol. NMR
4,
871-878
|
| 55.
|
Farmer, B. T.
(1996)
Nat. Struct. Biol.
3,
995-997
|
| 56.
|
Williamson, R. A.,
Carr, M. D.,
Frenkiel, T. A.,
Feeney, J.,
and Freedman, R. B.
(1997)
Biochemistry
36,
13882-13889
|
| 57.
|
Muskett, F. W.,
Frenkiel, T. A.,
Feeney, J.,
Freedman, R. B.,
Carr, M. D.,
and Williamson, R. A.
(1998)
J. Biol. Chem.
273,
21736-21743
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. E. Horsfall, G. Garau, B. M. R. Lienard, O. Dideberg, C. J. Schofield, J. M. Frere, and M. Galleni
Competitive Inhibitors of the CphA Metallo-{beta}-Lactamase from Aeromonas hydrophila
Antimicrob. Agents Chemother.,
June 1, 2007;
51(6):
2136 - 2142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Yamaguchi, T. Kuroki, H. Yasuzawa, T. Higashi, W. Jin, A. Kawanami, Y. Yamagata, Y. Arakawa, M. Goto, and H. Kurosaki
Probing the Role of Asp-120(81) of Metallo-{beta}-lactamase (IMP-1) by Site-directed Mutagenesis, Kinetic Studies, and X-ray Crystallography
J. Biol. Chem.,
May 27, 2005;
280(21):
20824 - 20832.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. R. Walsh, M. A. Toleman, L. Poirel, and P. Nordmann
Metallo-{beta}-Lactamases: the Quiet before the Storm?
Clin. Microbiol. Rev.,
April 1, 2005;
18(2):
306 - 325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Damblon, M. Jensen, A. Ababou, I. Barsukov, C. Papamicael, C. J. Schofield, L. Olsen, R. Bauer, and G. C. K. Roberts
The Inhibitor Thiomandelic Acid Binds to Both Metal Ions in Metallo-{beta}-lactamase and Induces Positive Cooperativity in Metal Binding
J. Biol. Chem.,
August 1, 2003;
278(31):
29240 - 29251.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Heinz, R. Bauer, S. Wommer, W. Meyer-Klaucke, C. Papamichaels, J. Bateson, and H.-W. Adolph
Coordination Geometries of Metal Ions in D- or L-Captopril-inhibited Metallo-{beta}-lactamases
J. Biol. Chem.,
May 30, 2003;
278(23):
20659 - 20666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Oelschlaeger, R. D. Schmid, and J. Pleiss
Insight into the mechanism of the IMP-1 metallo-{beta}-lactamase by molecular dynamics simulations
Protein Eng. Des. Sel.,
May 1, 2003;
16(5):
341 - 350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Siemann, D. P. Evanoff, L. Marrone, A. J. Clarke, T. Viswanatha, and G. I. Dmitrienko
N-Arylsulfonyl Hydrazones as Inhibitors of IMP-1 Metallo-{beta}-Lactamase
Antimicrob. Agents Chemother.,
August 1, 2002;
46(8):
2450 - 2457.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|